Source: FinanzNachrichten

Calliditas Therapeutics: Number of Shares and Votes in Calliditas Therapeutics

STOCKHOLM, June 30, 2020 /PRNewswire/ -- During June, Calliditas Therapeutics AB (publ) has issued 9,230,770 common shares as a result of the initial public offering on The Nasdaq Global Select Ma...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Renee Aguiar-Lucander's photo - CEO of Calliditas

CEO

Renee Aguiar-Lucander

CEO Approval Rating

90/100

Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Read more